ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Tamoxifen attenuates postsurgical hindlimb swelling and soft-tissue fibrosis in a rat model of secondary lymphatic injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Secondary lymphedema is a common complication after lymph node dissection and is characterized by chronic swelling and progressive soft-tissue fibrosis. Tamoxifen has been reported to exert antifibrotic and antioxidant effects. We investigated whether tamoxifen could attenuate postsurgical limb swelling and fibrosis in a rat model of secondary lymphatic injury and explored potential oxidative mechanisms. Forty Wistar-Albino rats were randomized into four groups (n = 10 each). A standardized right hindlimb lymphadenectomy was performed in all groups. Tamoxifen (2.5 mg/kg/day, oral) was administered with different schedules: 7 days preoperative + 7 days postoperative (Group 2), 14 days postoperative starting immediately (Group 3), and 14 days postoperative starting on day 14 (Group 4). Outcomes at day 30 included limb volume change (water volumetry), lymphoscintigraphy (Tc-99 m nanocolloid), histopathological fibrosis score, tissue hydroxyproline, oxidative stress markers, malondialdehyde (MDA) and glutathione (GSH), and selected cytokines. Lymphoscintigraphic parameters did not differ significantly between groups. However, postoperative volumetric increase of the operated limb was significantly greater in untreated controls than in Groups 2 and 3 (p < 0.05). Histopathologic fibrosis scores were significantly lower in Groups 2 and 3 compared to the controls, supported by lower hydroxyproline levels. Tissue MDA levels were higher and GSH levels lower in controls compared with treated groups., suggesting attenuation of oxidative stress by tamoxifen. In this rat model, tamoxifen reduced postsurgical limb swelling and soft-tissue fibrosis, accompanied by lower oxidative stress. However, lymphoscintigraphy did not demonstrate significant between-group differences and a sham-operated control group was not included. Thus, our findings support an antifibrotic/antioxidant effect of tamoxifen on postoperative tissue changes rather than lymphedema prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.